All News

Patients whose endurance increases will likely have a higher quality of life and ability to carry out daily functions, the authors said.

On this episode of Managed Care Cast, we interview the lead author of a paper in the Health IT issue of The American Journal of Managed Care.

Zanubrutinib is a second-generation Bruton tyrosine kinase (BTK) inhibitor that has fewer off-target effects and less cardiotoxicity than ibrutinib, a first-generation BTK inhibitor.

These new study findings support a link between faster walking pace and reduced risk of developing heart failure and its subtypes.

Implementing evidence-based guidelines (EBGs) resulted in a 17.3% reduction in anaphylaxis-related hospitalizations among children.

The data published in Scientific Reports are the first to implicate a role for RASGRP4 mutations in B-cell malignancies.

The trastuzumab biosimilar Herzuma was shown to have similar clinical efficacy and safety to the reference product in patients with HER2-positive advanced gastric cancer.

Patients with severe chronic rhinosinusitis with nasal polyps achieved significant improvements in health-related quality of life (HRQOL) and general health status with dupilumab treatment after 52 weeks.

A model developed by researchers in China could help identify patients with non–small cell lung cancer (NSCLC) most likely to benefit from anti– programmed death-ligand 1 (PD-L1) immunotherapy.

Findings of a pilot study suggest that gut microbiome differences resulting from environmental factors could affect racial disparities in type 2 diabetes.

An analysis conducted in Japan among patients with acute decompensated heart failure (HF) revealed excessive polypharmacy at hospital discharge is associated with an increased risk of mortality after 1 year.

Incidence of infectious diseases, skin infections, and systemic antibiotic exposure were all associated with the development of atopic dermatitis among infants and young children.

Research presented at the 2021 American Society of Hematology Annual Meeting and Exposition highlights efforts in screening for multiple myeloma (MM).

A study comparing 4 different artificial intelligence (AI) models found that some models were better than others at detecting early-stage chronic kidney disease (CKD), when patients do not experience visible symptoms.

The Biden administration will distribute 400 million nonsurgical N95 masks; a study aims to develop a questionnaire to enable gay and bisexual men to donate blood; counterfeit versions of Gilead HIV treatments were discovered in 9 states.

Patients with psoriatic disease and dermatologists reported their preferred strategies to improve cardiovascular disease risk management, with a specialist-led model of care touted by both groups.

With no existing respiratory syncytial virus (RSV) vaccine yet, researchers found that a vaccine comparable with the influenza vaccine could prevent tens of thousands of hospitalizations and deaths per year.

This new short-term matched study from investigators at Children’s Hospital of Philadelphia investigated cardiac-related outcomes among pediatric patients presenting with COVID-19–related multisystem inflammatory syndrome.

A mother in her early 30s received her HIV-1 diagnosis only after her child received their diagnosis of both HIV-1 and Pneumocystis jirovecii pneumonia at age 28 weeks.

A recent report from the CDC details varying incidences of breast cancer among women by demographic characteristics and suggests areas for improvement in treatment and patient education on risk.

There has not been a change in the standard of care in this type of cancer in a decade, according to an expert from ASCO.

Merck had previously received accelerated approval for pembrolizumab for patients with advanced hepatocellular carcinoma (HCC); an FDA panel left the approval in place while waiting on results from KEYNOTE-394.

Natural killer cell therapy CYNK-101 was granted fast track designation by the FDA to treat HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma in combination with standard chemotherapy, trastuzumab, and pembrolizumab.

An abstract presented at the 63rd American Society of Hematology (ASH) Annual Meeting and Exposition assessed real-world data on patients with multiple myeloma to provide insight into longitudinal testing patterns and rates of sustained minimal residual disease (MRD) negativity.

The report suggests remission and disease activity state alone are not the most important risk factors in pregnant women with well-controlled systemic lupus erythematosus.

Israeli study finds the added antibody protection from a fourth COVID-19 vaccine dose is not enough to prevent Omicron infection; Texas abortion law remains in effect after appeals court ruling; insurer spending for the unproven COVID-19 drug ivermectin was estimated at $2.5 million for a week last summer.

Stephen Schleicher, MD, MBA, and Natalie Dickson, MD, discuss their new roles as chief medical officer (CMO) and chief strategy officer (CSO), respectively, at Tennessee Oncology.

On this episode of Managed Care Cast, Mark Miller, PhD, the executive vice president of health care at Arnold Ventures, outlines what Americans can expect from the newly enacted No Surprises Act.

Victoria Ly, MD, MPH, explains potential next steps for her research on vision screening follow-up rate disparities among children in Arkansas.